To support the laboratory need for fast, comprehensive genomic profiling (CGP), Thermo Fisher introduces additions to its next generation sequencing line. The Genomic Instability Metric (GIM) is an approach to measure genomic scarring related to homologous recombination deficiency (HRD). The GIM is a complex endpoint generated from the firm’s Oncomine Comprehensive Assay (OCA) Plus, a targeted sequencing panel covering more than 500 genes. It studies genome segmentation to determine copy number changes, allele-specific copy number calls, and unbalanced copy number events to produce a score ranging from 1 to 99. Using cutoffs, GIM can call breast cancer samples as HRD positive or negative and can help stratify ovarian cancer samples.